search
Back to results

Low Carbohydrate Diet in Diabetic Kidney Disease

Primary Purpose

Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Obesity

Status
Completed
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Dietary advice
Sponsored by
Universiti Teknologi Mara
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring low carbohydrate diet, chronic kidney disease, diabetes mellitus

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Diagnosed with Type 2 DM of more than 5 years
  2. Diagnosis of stable CKD of more than 6 months
  3. CKD stage 2 and 3
  4. HbA1c of 7% - 10.5%
  5. Patient age between 40-75 years old
  6. Able to sign informed consent

Exclusion Criteria

  1. Type 1 DM
  2. Frequent hypoglycaemia
  3. Persistent elevations of serum transminase
  4. Heart failure (New York Heart Association functional class III-IV), active systemic inflammatory disease, chronic renal failure requiring hemodialysis, active hepatic disease and collagen disease
  5. Malignancy
  6. Recent hospital admission for acute within the past 3 months
  7. Pregnant women, breastfeeding or planning to conceive within the next year

Sites / Locations

  • Universiti Teknologi MARA

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Low carbohydrate diet (LCBD)

Low protein diet only (LPD)

Arm Description

Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.

Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.

Outcomes

Primary Outcome Measures

Change from baseline serum Creatinine at 12 weeks
Creatinine in micromol/L
Change from baseline urine microalbuminuria at 12 weeks
Urine microalbuminuria in mmol/L

Secondary Outcome Measures

Change from baseline HbA1c at 12 weeks
HbA1c in %
Change from baseline fasting plasma glucose at 12 weeks
FPG in mmol/L
Change from baseline lipid levels at 12 weeks
Cholesterol in mmol/L
Change from baseline weight at 12 weeks
Weight in kg
Change from baseline hip circumference (HC) at 12 weeks
HC in cm
Change from baseline waist circumference (WC) at 12 weeks
WC in cm
Change from baseline estimated visceral adispose tissue (Est VAT) at 12 weeks
Est VAT in %
Change from baseline blood pressure at 12 weeks
Blood pressure in mmHg
Change from baseline highly sensitivity C-reactive protein (hsCRP) at 12 weeks
hsCRP in nmol/L
Change from baseline Interleukin-6 (IL-6) at 12 weeks
IL-6 in pg/mL

Full Information

First Posted
June 1, 2021
Last Updated
June 10, 2021
Sponsor
Universiti Teknologi Mara
Collaborators
International Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04931030
Brief Title
Low Carbohydrate Diet in Diabetic Kidney Disease
Official Title
Effects of Low Carbohydrate Diet (LCBD) on Weight and Renal Outcome in Patients With Diabetic Kidney Disease (DKD)- A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
March 15, 2019 (Actual)
Primary Completion Date
March 5, 2021 (Actual)
Study Completion Date
March 5, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Teknologi Mara
Collaborators
International Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The current population of type 2 diabetes mellitus (T2DM) worldwide is over 200 million and Malaysia contributes to 1.2% of that number. The prevalence of T2DM in Malaysia has approximately tripled over the last three decades from 6.3% in 1986 to 17.5% of the adult population in 2015.T2DM is a progressive disease associated with debilitating microvascular and macrovascular complications. The prevalence of chronic kidney disease (CKD) in Peninsular Malaysia was high at 9.1% of the adult population in 2011. T2DM is the leading cause of renal failure for patients commencing dialysis, increasing from 53% of new dialysis patients in 2004 to 61% in 2013. Therefore, diabetic kidney disease (DKD) is a debilitating complication which not only imposes significant health problems but also confers financial burden on affected patients. There has been increasing amount of understanding in the complexity of the relationship between T2DM and obesity. As the prevalence of both conditions continue to demonstrate a parallel rise, the influence of obesity on T2DM is further marked. Thus, this has led to greater emphasis on weight loss in the management of T2DM. More recent anti-diabetic medications including SGLT-2 inhibitors and GLP1 agonists demonstrated greater efficacy in improving glycaemic control and their ability to produce weight reduction. In addition, there has been more interest in the effects of these drugs on retardation of renal disease progression. The mechanism is unclear, either attributed by direct drug effects on renal glomerular-tubular structures, through the Renin-Angiotensin-Aldosterone-System (RAAS), or other pathways. Another pausible explanation is the significant weight loss, which has been shown to have a significant effect of attenuation of renal disease. Weight reduction programs have long been a complex and tedious treatment plan which has inconsistent, non-duplicable and unpredictable outcomes. Most programs emphasized on medical nutrition therapy and lifestyle changes. There has been many different dietary plans which share a common goal ie to reduce calori intake whilst increasing energy expenditure. Few have been successfully reproducible, limited by either patient adherence or modest outcome. Low carbohydrate diet is a diet plan which stresses on reducing carbohydrate intake to less than 20g daily. Numerous studies have shown that weight loss could be obtained by reduction of calori intake in either the form of carbohydrate or fat. CKD patients are recommended to consume low protein diet of less than 0.6-0.7g/kg/day with little emphasis on calori or carbohydrate intake. This study, thus, aims to evaluate the effects of low carbohydrate and moderate fat (LCBD) in addition to low protein diet on renal disease in patients with DKD.
Detailed Description
This is an investigator-initiated, single center, randomized, controlled, clinical trial in Type 2 diabetes mellitus patients, comparing 16-weeks of LCBD compared to standard medical therapy in patients with DKD. Patients would be recruited from the Endocrinology and Nephrology clinics in UiTM Medical Specialist Center. Inclusion criteria would include patients aged between 40-75 years old, diagnosis with Type 2 DM of more than 5 years with stable CKD stage 2 and 3 of more than 6 months, HbA1c of 7% - 10.5%. Exclusion Criteria include patients with Type 1 DM, experiencing frequent hypoglycaemia, abnormal liver function tests, heart failure (New York Heart Association functional class III-IV), active systemic inflammatory disease, chronic renal failure requiring hemodialysis, active hepatic disease and collagen disease, malignancy, recent hospital admission within the past 3 months, pregnant women, breastfeeding or planning to conceive within the next year. Following informed consent, patients would be randomised to either LCBD or low protein Diet (LPD) group. All recruited patients will be given the standard dietary and exercise advice which will include low protein of 0.6-0.7g/kg/day and low salt diet. In addition, patients within the LCBD will be given a prescription diet of 20g of carbohydrate daily. This will be supplemented by visual aids on carbohydrate counts of various local food. Patients would be given the option to choose their most appropriate food types which will amount to the carbohydrate count given. Patients on oral anti-diabetic treatment including insulin will advised on titrations of their medications to avoid hypoglycaemia. The control arm will not be given any additional advice. All patients will be required to fill in a 3-day food diary during their scheduled visits which will be at 8 weeks and 16 weeks. Clinical assessments include blood sampling of approximately 8 ml which will be done at baseline and at study end.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Obesity
Keywords
low carbohydrate diet, chronic kidney disease, diabetes mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, controlled, unblinded, dietary intervention
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low carbohydrate diet (LCBD)
Arm Type
Experimental
Arm Description
Subjects are given a dietary prescription of 20g of carbohydrate daily in addition to standard low protein diet of 0.6-0.7g/kg/day and low salt diet.
Arm Title
Low protein diet only (LPD)
Arm Type
No Intervention
Arm Description
Subjects are given the standard dietary advice of chronic kidney disease of low protein diet of 0.6-0.7g/kg/day and low salt diet.
Intervention Type
Other
Intervention Name(s)
Dietary advice
Intervention Description
Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
Primary Outcome Measure Information:
Title
Change from baseline serum Creatinine at 12 weeks
Description
Creatinine in micromol/L
Time Frame
Study end at 12 weeks
Title
Change from baseline urine microalbuminuria at 12 weeks
Description
Urine microalbuminuria in mmol/L
Time Frame
Study end at 12 weeks
Secondary Outcome Measure Information:
Title
Change from baseline HbA1c at 12 weeks
Description
HbA1c in %
Time Frame
Study end at 12 weeks
Title
Change from baseline fasting plasma glucose at 12 weeks
Description
FPG in mmol/L
Time Frame
Study end at 12 weeks
Title
Change from baseline lipid levels at 12 weeks
Description
Cholesterol in mmol/L
Time Frame
Study end at 12 weeks
Title
Change from baseline weight at 12 weeks
Description
Weight in kg
Time Frame
Study end at 12 weeks
Title
Change from baseline hip circumference (HC) at 12 weeks
Description
HC in cm
Time Frame
Study end at 12 weeks
Title
Change from baseline waist circumference (WC) at 12 weeks
Description
WC in cm
Time Frame
Study end at 12 weeks
Title
Change from baseline estimated visceral adispose tissue (Est VAT) at 12 weeks
Description
Est VAT in %
Time Frame
Study end at 12 weeks
Title
Change from baseline blood pressure at 12 weeks
Description
Blood pressure in mmHg
Time Frame
Study end at 12 weeks
Title
Change from baseline highly sensitivity C-reactive protein (hsCRP) at 12 weeks
Description
hsCRP in nmol/L
Time Frame
Study end at 12 weeks
Title
Change from baseline Interleukin-6 (IL-6) at 12 weeks
Description
IL-6 in pg/mL
Time Frame
Study end at 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Diagnosed with Type 2 DM of more than 5 years Diagnosis of stable CKD of more than 6 months CKD stage 2 and 3 HbA1c of 7% - 10.5% Patient age between 40-75 years old Able to sign informed consent Exclusion Criteria Type 1 DM Frequent hypoglycaemia Persistent elevations of serum transminase Heart failure (New York Heart Association functional class III-IV), active systemic inflammatory disease, chronic renal failure requiring hemodialysis, active hepatic disease and collagen disease Malignancy Recent hospital admission for acute within the past 3 months Pregnant women, breastfeeding or planning to conceive within the next year
Facility Information:
Facility Name
Universiti Teknologi MARA
City
Petaling Jaya
State/Province
Selangor
ZIP/Postal Code
47000
Country
Malaysia

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Unidentified subjects' raw data is required for some journal submissions
Citations:
Citation
Feisul MI, Azmi S. (Eds). National Diabetes Registry Report, Volume 1, 2009-2012. Kuala Lumpur; Ministry of Health Malaysia; 2013 Jul.
Results Reference
background
Citation
National Health and Morbidity Survey 2015 (NHMS 2015). Ministry of Health, Kuala Lumpur, Malaysia
Results Reference
background
PubMed Identifier
23760287
Citation
Hooi LS, Ong LM, Ahmad G, Bavanandan S, Ahmad NA, Naidu BM, Mohamud WN, Yusoff MF. A population-based study measuring the prevalence of chronic kidney disease among adults in West Malaysia. Kidney Int. 2013 Nov;84(5):1034-40. doi: 10.1038/ki.2013.220. Epub 2013 Jun 12.
Results Reference
background
Citation
B. Goh, L. Ong, Y. Lim. Twenty First Report of the Malaysian Dialysis and Transplant 2013. Malaysian Society of Nephrology, Kuala Lumpur, Malaysia (2014)
Results Reference
background

Learn more about this trial

Low Carbohydrate Diet in Diabetic Kidney Disease

We'll reach out to this number within 24 hrs